Join the PDUFA run. Approval is a lock.
Probuphine for drug addiction is a $1.5 billion market in the US.
TTNP will earn a $50 million milestone upon approval on April 30.
Probuphine for chronic pain is an even larger market.
The ProNeura technology can be used with any small molecule drug going off patent to extend exclusivity.
This is huge!